九典制药集采中标核心产品，战略转型与研发进展并行

Core Viewpoint - The company, Jiudian Pharmaceutical, has won the bid for its core product, Loxoprofen Sodium Gel Patch, at the lowest price in the 11th national centralized procurement, which may pressure its gross margin in the short term, necessitating an increase in sales to cope with market competition [1] Business Strategy - The company has set a strategic goal for 2026 to drive growth through a dual approach of "stabilizing the existing business base and innovative transformation," ensuring sales of centralized procurement products in hospitals while expanding OTC channels and strengthening brand presence, as well as advancing the pipeline for innovative drug development [2] Product Development Progress - In the field of external preparations, the innovative drug JIJ02 gel is currently in the clinical stage, while the traditional Chinese medicine product, Jiao Qi Pain Relief Gel Patch, has been submitted for production approval. Unique products such as Ketoprofen Gel Patch and Daiwen Moxibustion Patch are prioritized for promotion [3] Company Status - The company plans to evaluate high-quality products or assets based on strategic needs and does not rule out acquisitions to enrich its product line. Additionally, it aims to establish a sustainable shareholder return plan based on operational performance and cash flow over the next 2-3 years [4]